



Atty. Dkt. No. 065691/0222

#5
#5/A.88
12/15/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Pierre Chambon et al.

Entitled: Transgenic Mouse for Targeted Recombination Medicated by Modified CRE-ER

Serial No. 09/853,033

Filing Date May 11, 2001

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of the present application, Applicant's respectfully requests that the above-identified application be amended as follows:

In the Claims:

In accordance with 37 C.F.R. § 1.121(c) (3), please substitute for pending claims 4-20, 25-29, 31-33, 35-38 and 52-56 with the following clean version of the claims. The changes to these claims are shown explicitly in the attached "Marked Up Version of Claims."

4. (Amended) Organism according Claim 1, characterized in that said sites of recognition specific for said Cre recombinase are preferably chosen from the group composed of the sequences Lox P, Lox 66, Lox 71, Lox 511, Lox 512, Lox 514.

5. (Amended) Organism according to Claim 1, characterized in that said hinge region comprises all or part of the D hinge region of a nuclear estrogen receptor, a region situated between the DNA-binding domain and the ligand-binding domain, or a peptide which is functionally equivalent to said D hinge region.